Overview

SMMART Adaptive Clinical Treatment (ACT) Trial

Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial determines if testing samples from a patients' cancer can be used to find specific drugs or drug combinations that can help control their disease. The safety and tolerability of the drug or drug combination is also to be studied. Another purpose is for researchers to study tumor cells to try to learn why some people respond to a certain therapy and others do not, and why some cancer drugs stop working.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Genentech, Inc.
Oregon Health and Science University
Treatments:
Ado-Trastuzumab Emtansine
Albumin-Bound Paclitaxel
Anastrozole
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Atezolizumab
Bevacizumab
Capecitabine
Carboplatin
Endothelial Growth Factors
Entrectinib
Fulvestrant
Immunoconjugates
Immunoglobulin G
Immunoglobulins
Immunoglobulins, Intravenous
Irinotecan
Letrozole
Maytansine
Niraparib
Olaparib
Paclitaxel
Palbociclib
Pertuzumab
Phosphoinositide-3 Kinase Inhibitors
Trastuzumab
Vemurafenib
Vinorelbine